[Fundamental and clinical evaluation of 9,3"-diacetylmidecamycin in pediatric field (author's transl)]

Jpn J Antibiot. 1982 Feb;35(2):429-37.
[Article in Japanese]

Abstract

1. The dry syrup of MOM was administered orally to 17 patients mainly with heart diseases at doses of 10 mg/kg and 20 mg/kg. In 17 cases, the serum level was measured and in 4 cases, the urinary excretion rate including the metabolites of MOM. 2. The mean maximal concentrations were 0.54 mcg/ml at 30 minutes for the group of 10 mg/kg treatment and 0.33 mcg/ml at 1 hour for the group of 20 mg/kg treatment. The dose response was not observed obviously in both groups. 3. In each of the cases, the sum of excretion rates of metabolites in the 24-hour urine was about 1%. 4. MOM was administered clinically to 39 cases with respiratory tract infections and the overall efficacy rate was 85%. 5. In this study, 5 strains of S. pyogenes were isolated and the eradication rate was 60%. 6. Although severe side effects were not observed, gastrointestinal abnormalities like diarrhea and vomiting were seen in 3 cases. 7. Any pediatric patient did not refuse taking.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Age Factors
  • Bacterial Infections / drug therapy*
  • Child
  • Child, Preschool
  • Drug Evaluation
  • Female
  • Humans
  • Leucomycins / administration & dosage
  • Leucomycins / adverse effects
  • Leucomycins / metabolism*
  • Male
  • Miocamycin
  • Respiratory Tract Infections / drug therapy*
  • Respiratory Tract Infections / microbiology

Substances

  • Leucomycins
  • Miocamycin
  • midecamycin